Date: 2011-04-19
Type of information: Licensing agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: Medigene (Germany) Triton Pharma (Canada)
Therapeutic area: Gynecology - Infectious diseases
Type agreement: licensing
supply
commercialisation
Action mechanism:
Disease: External genital warts
Details: MediGene AG has signed an exclusive license and supply agreement with the Canadian company Triton Pharma Inc. for the supply and commercialization of Veregen® ointment for the treatment of genital warts in Canada. Triton will be responsible for the drug approval procedure in Canada. MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland, with Laboratoires Expanscience for France, and with a number of other partners across Europe, America, and Asia. MediGene is planning to continue this global licensing strategy. Veregen® is currently available on the US, German, and Austrian markets. A second wave of marketing applications within the European mutual recognition procedure is planned, with Germany serving as the reference state in this process.
Financial terms: MediGene is entitled to successive payments totaling up to € 2.1 million, due upon the achievement of set milestones. It will obtain royalties on the sales revenue generated with Veregen® in the form of a double-digit percentage share.
Latest news:
